DOI QR코드

DOI QR Code

Studies on the Nootropic and Anti-amnestic and Anxiolytic-like Effects of G.J.D-P.P.A. in Mice

공진단(拱辰丹)과 영신초(靈神草), 원지(遠志), 석창포(石菖蒲) 혼합제제의 기억력과 인지기능 개선 및 항불안에 관한 연구

  • Choi, Cheol-Hong (Dept. of Oriental Neuropsychiatry, College of Oriental Medicine, Daegu Haany University) ;
  • Kim, Soo-Hyun (Dept. of Oriental Neuropsychiatry, College of Oriental Medicine, Daegu Haany University) ;
  • Chung, Dae-Kyoo (Dept. of Oriental Neuropsychiatry, College of Oriental Medicine, Daegu Haany University)
  • 최철홍 (대구한의대학교 한의과대학 신경정신과학교실) ;
  • 김수현 (대구한의대학교 한의과대학 신경정신과학교실) ;
  • 정대규 (대구한의대학교 한의과대학 신경정신과학교실)
  • Received : 2011.05.09
  • Accepted : 2011.06.13
  • Published : 2011.06.30

Abstract

Objectives : The purpose of this study was to characterize the neuroprotective effects and anxiolytic-like effects of Gongjin-dan and Polygala japonica, Polygala tenuifolia, Acorus gramineus mixed pills(G.J.D-P.P.A.). Methods : The neuroprotective effects of G.J.D-P.P.A. determined by the passive avoidance and Y-maze tasks and Morris water maze task, and the anxiolytic-like effects of the G.J.D-P.P.A. using an elevated plus-maze(EPM) in mice. Results : Drug-induced amnesia was induced by treating animals with scopolamine(1 mg/kg, i.p.). A single G.J.D-P.P.A.(400 and 800 mg/kg) administration significantly enhanced cognitive function and attenuated scopolamine-induced cognitive impairments as determined by the passive avoidance and Y-maze tasks(P < 0.05) and also reduced escape-latency on the Morris water maze task(P < 0.05). The administration of GJD-PPA(400 and 800 mg/kg) significantly increased the percentage of time spent in open arms and entries into the open arms of the EPM compared with saline-treated control group(P < 0.05). Moreover, there were no changes in the locomotor activity and myorelaxant effects in any group compared with saline-treated control group. Conclusions : These results suggest that GJD-PPA dramatically possesses the anti-amnestic and cognitive-enhancing activities related to the memory processes, and promotes the anxiolytic-like activity in mice.

Keywords

References

  1. 대한한방신경정신과학회 편. 한방신경정신의학. 파주:집문당. 2006:117-24, 125-30, 203-12.
  2. 민성길. 최신정신의학. 서울:一潮閣. 2005:189-98, 297-329.
  3. Ferretti L, McCurry SM, Logsdon R, Gibbons L, Teri L. Anxiety and Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology. 2001;14(1):52-8. https://doi.org/10.1177/089198870101400111
  4. Mattson MP, Barger SW, Furukawa K, Bruce AJ, Wyss-Coray T, Mark RJ, Mucke L. Cellilar signaling roles of $TGF\beta,\;TNF\alpha\;and\;{\beta}APP$ in brain injury responses and Alzheimer's disease. Brain Res Rev. 1997;23:47-61. https://doi.org/10.1016/S0165-0173(96)00014-8
  5. Giacobini E. Present and future of Alzheimer therapy. J Neural Transm Suppl. 2000;59:231-42.
  6. Chouinard G, Lefko-Singh K, Teboul E. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. CellMolNeurobiol. 1999;19(4):533-52
  7. 張介賓. 張氏景岳全書. 서울:翰成社. 1978:610-1.
  8. 陳士澤. 國譯石室秘錄. 서울:書苑堂. 1984:102.
  9. 虞博. 醫學正傳. 北京:人民衛生出版社. 1963:274.
  10. 李梴. 醫學入門. 서울:南山堂. 1982:487-8.
  11. 陳輝. 實用中醫腦病學. 北京:學苑出版社. 1993:242-51, 784-91.
  12. 危亦林. 世醫得效方. 北京:人民衛生出版社. 1990:271.
  13. 許浚. 東醫寶鑑. 서울:법인문화사. 1999:189-90,1180.
  14. 이은경. 靈神草의 항우울 효과에 대한 행동 약리학적 연구. 대구한의대학교 대학원 박사학위 논문. 2009.
  15. 한신희, 길기정. 인삼산사복합방(人蔘山査複合方)이 Alzheimer성 치매 병태(病態) 생쥐의 뇌조직 손상에 미치는 효과. 대한본초학회지. 2006;21(4):123-31.
  16. 손세규, 임채광, 김광중. Elevated plus-maze를 이용한 芍藥甘草湯의 항불안 효과. 동서의학. 2010;35(3):107-23.
  17. LeDoux JE. Emotional memory system in the brain. Behav Brain Res. 1993;58(1-2):69-79. https://doi.org/10.1016/0166-4328(93)90091-4
  18. Ebert, U. Kirch, W. Scopolamine model of dementia: electro- encephalogram findings and cognitive performance. Eur J Clin Invest. 1998;28(11):944-9. https://doi.org/10.1046/j.1365-2362.1998.00393.x
  19. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11(1):47-60. https://doi.org/10.1016/0165-0270(84)90007-4
  20. Yamaguchi Y, Miyashita H, Tsunekawa H, Mouri A, Kim HC, Saito K, Matsuno T, Kawashima S, Nabeshima T. Effects of a novel cognitive enhancer spiro[imidazo-[1,2-a]pyridine-3,2-indan]-2(3H)-one(ZSET1446), on learning impairments induced by amyloid-beta 1-40 in the rat. J Pharmacol. 2006;317(3):1079-87.
  21. Ellman, GL, courtney KD, Andres JV and Feather-Stone RM. A new and rapid colormetric determination of acetylcholinesterase activity. Biochem., Pharmacol. 1961;7:88-95. https://doi.org/10.1016/0006-2952(61)90145-9
  22. Handley SR, Tricklebank MD. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch Pharmacol. 1995;327:1-5.
  23. Overstreet DH, Pucilowski O, Rezvani AH, Janowsky DS. Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Psychopharmacology(Berl). 1995;121(1):27-37. https://doi.org/10.1007/BF02245589
  24. Hattesohl M, Feistel B, Sievers H, Lehnfeld R, Hegger M, Winterhoff H. Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine. 2008;15(1-2):2-15. https://doi.org/10.1016/j.phymed.2007.11.027
  25. 조맹제, 김기웅, 김병희, 김문두, 김봉조, 김신겸 등. 치매 노인 유병률 조사. 보건복지가족부. 2008.
  26. 조은영, 조은희, 김소선. 가족 상호관계가 치매노인 가족원의 부담감에 미치는 영향. 한국노년학. 2010;30(2):421-37.
  27. 오세관. 신경전달물질과 뇌질환. 서울:신일상사. 2005:345-64.
  28. Bains JS, Shaw CA. Neurodegeneration disorders in humans: The role of glutathione in oxidative stress-mediated neuronal death. Brain Research Review. 1997;25:335-58. https://doi.org/10.1016/S0165-0173(97)00045-3
  29. 이가옥. 노인생활실태 분석 및 정책과제. 한국보건사회연구원. 1994;114-32.
  30. Mattson MP, Chan SL, Camandola S. Presenilin mutations and calcium signaling defects in the nervous and immune system. Bioessays. 2001;23(8):733-44. https://doi.org/10.1002/bies.1103
  31. Trabace L, Cassano T, Steardo L, Pietra C, Villetti G, Kendrick KM, Cuomo V. Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. J Pharmacol Exp Ther. 2000;294(1):187-94.
  32. Trabace L, Cassano T, Steardo L, Pietra C, Villetti G, Kendrick KM, Cuomo V. Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. J Pharmacol Exp Ther. 2000;294(1):187-94.
  33. Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev. 2000;(4):CD001015.
  34. Womer DE, Shannon HE. Reversal of pertussis toxin-induced thermal allodynia by muscarinic cholinergic agonists in mice. Neuropharmacology. 2000;39(12):2499-504. https://doi.org/10.1016/S0028-3908(00)00068-X
  35. Ventura M, Sternon J. Anticholinesterase agents in Alzheimer's disease. Rev Med Brux. 2001;22(4):387-93.
  36. Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav. 1998;60(2):377-86. https://doi.org/10.1016/S0091-3057(97)00601-1
  37. Greenwald BS, Kramer-Ginsberg E, Marin DB, Laitman LB, Hermann CK, Mohs RC, Davis KL. Dementia with coexistent major depression. American Journal of Psychiatry. 1989;146:1472-8. https://doi.org/10.1176/ajp.146.11.1472
  38. 박건우. 치매의 행동신경심리증상에 대한 비약물학적 접근. 대한치매학회지. 2004;3(1):24-8.
  39. Sandford JJ, Argyropoulos SV, Nutt DJ. The psychobiology of anxiolytic drugs. Part1: Basic neruobiology. Pharmacol. Ther. 2000;88:197-212. https://doi.org/10.1016/S0163-7258(00)00082-6
  40. 한설희. 치매의 행동심리증상의 개관. 대한치매학회지. 2004;3(1):1-4.
  41. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. Clin Psychiatry. 1996;57(10):449-54. https://doi.org/10.4088/JCP.v57n1002
  42. Hoffman EJ, Mathew SJ. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med. 2008;75(3):248-62. https://doi.org/10.1002/msj.20041
  43. 洪元植. 精校黃帝內經靈樞素問. 서울:東洋醫學硏究院. 1985:37, 68, 124, 196, 217-8, 229, 229, 342.
  44. 王淸任. 醫林改錯. 台北:中國醫藥叢書. 1975:22-5.
  45. 이근후 외. 최신임상정신의학. 서울:하나의학사. 1988:138, 216-28.
  46. 成無己. 傷寒明理論. 上海:科學技術出版社. 1980:28.
  47. 전국한의과대학본초학교수 편. 本草學. 서울:永林社. 1999:496-7, 520-2, 523-4, 545-6, 578-80, 626-7.
  48. Hsieh MT, Peng WH, Wu CR, Ng KY, Cheng CL, Xu HX. Review on experimental research of herbal medicines with anti-amnesic activity. Planta Med. 2010;76(3):203-17. https://doi.org/10.1055/s-0029-1240707
  49. Park CH, Lee YJ, Lee SH, Choi SH, Kim HS, Jeong SJ, Kim SS, Suh YH, Dehydroevodiamine-HCl prevents impairment of learning and memory and neuronal loss in rat models of cognitive disturbance. J Neurochem. 2000;74(1):244-53.
  50. 황선미, 정대규. 拱辰丹이 CT105로 유도된 Alzheimer's disease 病態 모델에 미치는 영향. 동의신경정신과학회지. 2004;15(2):103-18.
  51. 김경호, 정현우, 이동원, 김정숙, 김영균, 조수인. 遠志 추출물이 사회 심리적 스트레스에 미치는 영향. 대한본초학회지. 2003;18(1):99-108.
  52. 최혁, 김상호, 이대용, 안대종, 강형원, 류영수. pCT105로 유도된 치매모델에서 石菖蒲 수추출액이 미치는 영향. 동의신경정신과학회지. 2002;13(2):173-94.

Cited by

  1. Anxiolytic-like Effects of the Methanol Extract of Sophorae Fructus vol.19, pp.5, 2012, https://doi.org/10.11002/kjfp.2012.19.5.767